Patents by Inventor Maurizio Grimaldi

Maurizio Grimaldi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200171040
    Abstract: Methods for enhancing memory and/or learning and prevent neurodegeneration by administration of certain heterocyclic and aromatic compounds are described. The methods are particularly useful for treating patients suffering from a neurodegenerative disease such as (without limitation) Alzheimer's, Parkinsons's, Lou Gehrig's (ALS) disease or memory or learning impairment. A neuronal human cell-based assay that assess NF-kB gene up-regulation using a luciferase reporter is also provided that screens for compounds useful in methods for enhancing memory or learning.
    Type: Application
    Filed: July 8, 2019
    Publication date: June 4, 2020
    Inventors: Maurizio Grimaldi, Judith Varady Hobrath, Subramaniam Ananthan, Joseph A. Maddry
  • Publication number: 20190083505
    Abstract: Methods for enhancing memory and/or learning and prevent neurodegeneration by administration of certain heterocyclic and aromatic compounds are described. The methods are particularly useful for treating patients suffering from a neurodegenerative disease such as (without limitation) Alzheimer's, Parkinsons's, Lou Gehrig's (ALS) disease or memory or learning impairment. A neuronal human cell-based assay that assess NF-kB gene up-regulation using a luciferase reporter is also provided that screens for compounds useful in methods for enhancing memory or learning.
    Type: Application
    Filed: March 8, 2018
    Publication date: March 21, 2019
    Inventors: Maurizio GRIMALDI, Judith Varady HOBRATH, Subramaniam ANANTHAN, Joseph A. MADDRY
  • Patent number: 9980969
    Abstract: The invention provides methods of enhancing memory and/or learning and prevent neurodegeneration, comprising administering therapeutically effective amounts of certain heterocyclic and aromatic compounds to a patient in need thereof. In one aspect, the invention provides methods of treating patients suffering from a neurodegenerative disease, such as but not limited to, Alzheimer's, Parkinsons's, Lou Gehrig's (ALS) disease, and/or memory or learning impairment. The invention further provides neuronal human cell-based assays that assess NF-kB gene upregulation using a luciferase reporter, wherein the assays identify compounds that are useful in enhancing memory or learning.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: May 29, 2018
    Assignee: SOUTHERN RESEARCH INSTITUTE
    Inventors: Maurizio Grimaldi, Judith Varady Hobrath, Subramaniam Ananthan, Joseph A. Maddry
  • Publication number: 20160022691
    Abstract: Methods for enhancing memory and/or learning and prevent neurodegeneration by administration of certain heterocyclic and aromatic compounds are described. The methods are particularly useful for treating patients suffering from a neurodegenerative disease such as (without limitation) Alzheimer's, Parkinsons's, and Lou Gehrig's (ALS) disease or memory or learning impairment. A neuronal human cell-based assay that assess NF-kB gene up-regulation using a luciferase reporter is also provided that screens for compounds useful in methods for enhancing memory or learning.
    Type: Application
    Filed: July 13, 2015
    Publication date: January 28, 2016
    Inventors: Maurizio Grimaldi, Judith Varady Hobrath, Subramaniam Ananthan, Joseph A. Maddry
  • Patent number: 9095596
    Abstract: Methods for enhancing memory and/or learning and prevent neurodegeneration by administration of certain heterocyclic and aromatic compounds are described. The methods are particularly useful for treating patients suffering from a neurodegenerative disease such as (without limitation) Alzheimer's, Parkinsons's, Lou Gehrig's (ALS) disease or memory or learning impairment. A neuronal human cell-based assay that assess NF-kB gene up-regulation using a luciferase reporter is also provided that screens for compounds useful in methods for enhancing memory or learning.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: August 4, 2015
    Assignee: Southern Research Institute
    Inventors: Maurizio Grimaldi, Judith Varady Hobrath, Subramaniam Ananthan, Joseph A. Maddry
  • Publication number: 20120245166
    Abstract: Methods for enhancing memory and/or learning and prevent neurodegeneration by administration of certain heterocyclic and aromatic compounds are described. The methods are particularly useful for treating patients suffering from a neurodegenerative disease such as (without limitation) Alzheimer's, Parkinsons's, Lou Gehrig's (ALS) disease or memory or learning impairment. A neuronal human cell-based assay that assess NF-kB gene up-regulation using a luciferase reporter is also provided that screens for compounds useful in methods for enhancing memory or learning.
    Type: Application
    Filed: October 14, 2010
    Publication date: September 27, 2012
    Applicant: Southern Research Institute
    Inventors: Maurizio Grimaldi, Judith Varady Hobrath, Subramaniam Ananthan, Joseph A. Maddry
  • Publication number: 20110060000
    Abstract: Disclosed are methods and compositions for treating gliomas that involve quinacrine and other acridine analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 10, 2011
    Inventors: Maurizio Grimaldi, Subramaniam Ananthan
  • Publication number: 20040014678
    Abstract: Compositions and methods for inhibiting neurotoxic ubiquitin-proteasome proteolysis, and treatment of neurodegenerative disorders. In particular, a method of suppressing the neurotoxic effect of &bgr;-amyloid peptide, by administering an inhibitor to block &bgr;-amyloid peptide-mediated ubiquitin-proteasome proteolysis. Preferred inhibitors are inhibitors of ubiquitination, such as leucine-alanine dipeptide, and inhibitors of post-ubiquitination proteasome activity, such as lactacystin.
    Type: Application
    Filed: February 10, 2003
    Publication date: January 22, 2004
    Inventors: Antonella Favit, Maurizio Grimaldi, Daniel L. Alkon
  • Patent number: 6630507
    Abstract: Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention.
    Type: Grant
    Filed: February 2, 2001
    Date of Patent: October 7, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Aidan J. Hampson, Julius Axelrod, Maurizio Grimaldi
  • Patent number: 6107050
    Abstract: The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells. Another method utilizes the differential effects of .beta.-amyloid protein on levels of the protein kinase C isoenzymes PKC.alpha. and PKC.gamma. in Alzheimer's and normal cells. Yet another method detects Eu-TTA fluorescence differences between Alzheimer's and normal cells treated with an activator of a receptor-mediated metabolic pathway. In addition a diagnostic index for improved assessment between Alzheimer's and non Alzheimer's cells is provided.
    Type: Grant
    Filed: May 11, 1998
    Date of Patent: August 22, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Daniel L. Alkon, Antonelle R. Favit, Maurizio Grimaldi